51,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
  • Broschiertes Buch

Chronic hepatitis is an overarching problem of digestive diseases. According to WHO, more than 170 million people have chronic hepatitis C, and there are more than 2 billion people with evidence of ongoing or completed viral hepatitis B infection. Based on research from a large international study, the following conclusions have been drawn, namely that mortality from chronic viral hepatitis is comparable to tuberculosis, malaria and HIV. The study of new parameters for predicting the nature of the course, the rate of progression of liver fibrosis, and the risk of HCC development is of…mehr

Produktbeschreibung
Chronic hepatitis is an overarching problem of digestive diseases. According to WHO, more than 170 million people have chronic hepatitis C, and there are more than 2 billion people with evidence of ongoing or completed viral hepatitis B infection. Based on research from a large international study, the following conclusions have been drawn, namely that mortality from chronic viral hepatitis is comparable to tuberculosis, malaria and HIV. The study of new parameters for predicting the nature of the course, the rate of progression of liver fibrosis, and the risk of HCC development is of particular importance. In this direction, great prospects are opened in the field of genomics. Circulating microRNA-122 was evaluated as potential non-invasive biomarkers of liver fibrosis activation and prognosis in patients with chronic viral hepatitis. Micro-RNAs are early potential markers for diagnosis and monitoring of liver tissue status, including fibrosis and carcinogenesis processes.
Autorenporträt
Dinara Ayupovna Parpibaeva, born in 1970. Graduated from the Faculty of Medicine of TSMI-1. In 2021 received the degree of Doctor of Medical Sciences (DSc), Associate Professor, Head of Clinical Modelling Department of Tashkent Medical Academy. Published more than 100 scientific papers.